German Alvarez, MD
Family Medicine · Brandon, FLNPI 1619141231
Payments from drug & device makers
Across 393 payments — averaging $12,516 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$1.3M
- Axsome Therapeutics, Inc.$1.1M
- Astrazeneca UK Limited$477K
- Eli Lilly$389K
- Novartis$321K
- AstraZeneca$260K
- plus $1.1M from 17 others
Across 6 payments — averaging $2997.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vifor (international) Ltd.$12K
- Eli Lilly$6K
What the payments were for
- Food & beverage$16100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 167 | $1,320,984 |
| Axsome Therapeutics, Inc. | 26 | $1,065,983 |
| Astrazeneca UK Limited | 2 | $477,228 |
| Eli Lilly | 6 | $389,440 |
| Novartis | 1 | $321,471 |
| AstraZeneca | 1 | $260,224 |
| Sage Therapeutics, LLC | 24 | $217,478 |
| Boehringer Ingelheim | 8 | $167,159 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 46 | $143,779 |
| Vertex | 3 | $125,977 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 8 | $118,041 |
| Merck | 7 | $90,402 |
| Akebia Therapeutics Inc | 18 | $63,460 |
| Novo Nordisk AS | 9 | $47,102 |
| Avanir Pharmaceuticals, Inc. | 17 | $43,183 |
| Sagent Pharmaceuticals | 3 | $30,304 |
| Alnylam Pharmaceuticals Inc. | 3 | $16,435 |
| Vifor (international) Ltd. | 12 | $11,400 |
| Abbott | 20 | $5,853 |
| Kowa Research Institute, Inc. | 1 | $2,139 |
| Boehringer Ingelheim International GmbH | 9 | $657 |
| Phadia US Inc. | 1 | $16 |
| Amgen | 1 | $5 |
How this compares
$4,918,721 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 204 | $64,135 |
| DovatoDolutegravir Sodium/Lamivudine | 12 | $37,975 |
| SantylCollagenase Clostridium Hist. | 18 | $17,365 |
| ErtapenemErtapenem Sodium | 42 | $16,620 |
| XareltoRivaroxaban | 27 | $7,885 |
| LithostatAcetohydroxamic Acid | 12 | $6,382 |
| EntrestoSacubitril/Valsartan | 13 | $5,787 |
| Atorvastatin Calcium | 301 | $4,770 |
| JardianceEmpagliflozin | 18 | $4,242 |
| Oxcarbazepine | 55 | $4,210 |
| Vancomycin Hcl | 20 | $3,801 |
| Pantoprazole Sodium | 113 | $3,368 |
| Midodrine Hcl | 37 | $3,107 |
| Gabapentin | 161 | $2,801 |
| Levetiracetam | 73 | $2,493 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $321,471 | $5,78713 claims |
| Boehringer IngelheimJardiance | $167,159 | $4,24218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Brandon
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.